Our lab is focused on developing novel therapeutic strategies that target leukemia and leukemia stem cells. Using chemical and genetic approaches, our laboratory investigates targeting protein synthesis and degradation pathways in the mitochondria and cytoplasm. Mechanistic studies are coupled with preclinical evaluation to understand the biology of leukemia stem cells and highlight therapeutic strategies with potential therapeutic windows. In addition to acting as biological tools, these molecules also serve as leads for potential new treatment strategies. For example, using these approaches, we have demonstrated that acute myeloid leukemia (AML) cells and stem cells have a unique reliance on mitochondrial metabolism and have heightened sensitivity to inhibitors of mitochondrial translation. We have also demonstrated increased lysosomal mass in AML cells and increased sensitivity to lysosome disruption in this disease. To rapidly identify and test new therapeutic strategies in early proof-of-principle clinical trials, the Schimmer lab has also advanced compounds directly from the lab into Phase I clinical trials.
Aaron D Schimmer
Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
Clin Lymphoma Myeloma Leuk. 2017 Jun 29;:
Cancer Discov. 2017 Jul;7(7):670-672
Psychooncology. 2017 Jun 30;:
Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.
Leuk Res. 2017 Jun 01;59:93-96
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
Leuk Lymphoma. 2017 Jun 09;:1-4
Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):215-219
Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Int J Lab Hematol. 2017 Mar 20;:
Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
Blood. 2017 Mar 10;:
Leukemia. 2017 Jan 23;:
Longitudinal assessment of physical and psychological function in older patients with acute myeloid leukemia (AML): A pilot study.
J Clin Oncol. 2004 Jul 15;22(14_suppl):8273
Senior Scientist, Princess Margaret Cancer Centre
Professor, Department of Medical Biophysics, University of Toronto
Staff Physician, Leukemia Site Group, Princess Margaret Cancer Centre